Literature DB >> 23395802

Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy.

Rodrigo Donalisio da Silva1, Evanguelos Xylinas, Luis Kluth, Joseph J Crivelli, James Chrystal, Daher Chade, Giuliano Betoni Guglielmetti, Armin Pycha, Yair Lotan, Pierre I Karakiewicz, Maxine Sun, Harun Fajkovic, Marc Zerbib, Douglas S Scherr, Shahrokh F Shariat.   

Abstract

PURPOSE: Statins are cholesterol lowering agents used to prevent cardiovascular disease. Evidence suggests a dichotomous effect of statins with cancer inhibiting and promoting properties. To our knowledge the effect of statins on the prognosis of muscle invasive urothelial carcinoma of the bladder remains uninvestigated to date. We tested the hypothesis that statin use impacts oncological outcomes in patients treated with radical cystectomy for urothelial carcinoma of the bladder.
MATERIALS AND METHODS: We retrospectively evaluated the records of 1,502 patients treated with radical cystectomy and pelvic lymphadenectomy without neoadjuvant therapy at a total of 4 institutions. Cox regression models were used to determine the association of statins with disease recurrence and cancer specific mortality.
RESULTS: A total of 642 patients (42.7%) were on statins. At a median followup of 34 months 509 patients (33.9%) experienced disease recurrence and 402 (26.8%) had died of urothelial carcinoma of the bladder. Statin users were older (p = 0.003), had a higher body mass index (median 32 vs 28 kg/m(2), p <0.001) and were more likely to have positive soft tissue surgical margins (9% vs 4%, p <0.001). On univariable Cox regression analysis statins, female gender, advanced age, higher body mass index, smoking status, tumor stage, tumor grade, soft tissue surgical margin status, lymphovascular invasion, lymph node metastasis and adjuvant chemotherapy were associated with disease recurrence (p ≤ 0.05) and cancer specific mortality (p ≤ 0.02). On multivariable Cox regression analysis statin use was not associated with either outcome.
CONCLUSIONS: Statin users were at higher risk for disease recurrence and cancer specific mortality on univariable but not multivariable analysis. These data do not support modification of statin use in patients with high risk urothelial carcinoma of the bladder who will be treated with radical cystectomy.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMI; CIS; LVI; RC; STSM; UCB; body mass index; carcinoma in situ; hydroxymethylglutaryl-CoA reductase inhibitors; lymphovascular invasion; mortality; neoplasm recurrence; positive soft tissue surgical margin; radical cystectomy; urinary bladder; urinary bladder neoplasms; urothelial carcinoma of bladder

Mesh:

Substances:

Year:  2013        PMID: 23395802     DOI: 10.1016/j.juro.2013.02.003

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients.

Authors:  Shenghua Liu; Tian Yang; Rong Na; Mengbo Hu; Limin Zhang; You Fu; Haowen Jiang; Qiang Ding
Journal:  Int Urol Nephrol       Date:  2015-04-19       Impact factor: 2.370

2.  Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.

Authors:  Annemarie Greife; Jitka Tukova; Christine Steinhoff; Simon D Scott; Wolfgang A Schulz; Jiri Hatina
Journal:  Tumour Biol       Date:  2015-01-08

3.  Optimal body mass index cut-point for predicting recurrence-free survival in patients with non-muscle-invasive urothelial carcinoma of bladder.

Authors:  Satoru Yonekura; Fumihito Terauchi; Kenji Hoshi; Takehiko Yamaguchi; Shigeo Kawai
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

4.  Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis.

Authors:  Lijin Zhang; Bin Wu; Zhenlei Zha; Hu Zhao; Jun Yuan; Yuefang Jiang
Journal:  World J Urol       Date:  2019-03-27       Impact factor: 4.226

5.  Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer.

Authors:  Louise Emilsson; Xabier García-Albéniz; Roger W Logan; Ellen C Caniglia; Mette Kalager; Miguel A Hernán
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

6.  Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma.

Authors:  Ju Hyun Lim; In Gab Jeong; Jong Yeon Park; Dalsan You; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Korean J Urol       Date:  2015-06-30

7.  Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection.

Authors:  Antonio Pastore; Giovanni Palleschi; Andrea Fuschi; Luigi Silvestri; Yazan Al Salhi; Elisabetta Costantini; Alessandro Zucchi; Vincenzo Petrozza; Cosimo de Nunzio; Antonio Carbone
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

8.  Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.

Authors:  Kyle B Zuniga; Rebecca E Graff; David B Feiger; Maxwell V Meng; Sima P Porten; Stacey A Kenfield
Journal:  Bladder Cancer       Date:  2020-03-28

9.  Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro.

Authors:  Minyong Kang; Chang Wook Jeong; Ja Hyeon Ku; Choel Kwak; Hyeon Hoe Kim
Journal:  Int J Mol Sci       Date:  2014-05-08       Impact factor: 5.923

10.  The Prognostic Effect of Statin Use on Urologic Cancers: An Updated Meta-Analysis of 35 Observational Studies.

Authors:  You Luo; Dong-Li She; Hu Xiong; Sheng-Jun Fu; Li Yang
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.